Mira Pharmaceuticals (NASDAQ: MIRA) faces Nasdaq minimum bid price warning
Rhea-AI Filing Summary
Mira Pharmaceuticals, Inc. received a notice from Nasdaq on July 27, 2026 that its common stock no longer satisfies the Nasdaq Capital Market Minimum Bid Price Requirement, because the closing bid was below $1 per share for 30 consecutive business days ended July 24, 2026.
The stock continues to trade under the symbol MIRA while the company has 180 calendar days, until January 25, 2027, to regain compliance by maintaining a closing bid of at least $1 for at least ten consecutive business days. A second 180‑day cure period may be available if other listing standards are met and the company plans a cure, potentially including a reverse stock split. If compliance is not restored, the shares may be delisted, though the company could appeal any delisting determination to a Nasdaq Hearings Panel. Mira Pharmaceuticals plans to monitor its share price and consider options to address the deficiency, but there is no assurance compliance will be regained.
Positive
- None.
Negative
- Nasdaq has issued a minimum bid price deficiency notice, creating potential delisting risk if compliance is not regained.
Filing Explained
If Mira uses a reverse stock split as a cure, it would reduce the number of common shares and proportionally raise the per-share price; the split itself would not change company value, and the filing presents this as a possible future option rather than a completed action.
8-K Event Classification
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
1 item
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice or transferred its listing to a different exchange.
Key Figures
Minimum Bid Price Requirement: $1 per share
Non-compliance measurement period: 30 consecutive business days
Initial cure period: 180 calendar days
+1 more
4 metrics
Minimum Bid Price Requirement
$1 per share
Nasdaq Listing Rule 5550(a)(2) minimum closing bid price
Non-compliance measurement period
30 consecutive business days
Period ended July 24, 2026 during which bid was below $1
Initial cure period
180 calendar days
Time allowed to regain compliance, ending January 25, 2027
Potential additional cure period
180 calendar days
May be available if other Nasdaq listing standards are met
Key Terms
Minimum Bid Price Requirement, Nasdaq Capital Market, reverse stock split, Nasdaq Hearings Panel
4 terms
Minimum Bid Price Requirement regulatory
"the Company no longer meets the requirement to maintain a minimum bid price"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Capital Market regulatory
"The Letter has no immediate effect on the listing of the Common Stock"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
reverse stock split financial
"by effecting a reverse stock split, if necessary"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
Nasdaq Hearings Panel regulatory
"the Company may appeal the Staff’s delisting determination to a Nasdaq Hearings Panel"
A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What Nasdaq notice did Mira Pharmaceuticals (MIRA) receive on July 27, 2026?
Mira Pharmaceuticals received a Nasdaq notice that its stock no longer meets the $1 minimum bid price rule after trading below that level for 30 consecutive business days ended July 24, 2026, triggering a compliance remediation period.
How can Mira Pharmaceuticals (MIRA) regain compliance with Nasdaq’s $1 minimum bid rule?
To regain compliance, Mira’s common stock must post a closing bid price of at least $1 per share for a minimum of ten consecutive business days during the 180‑day grace period ending January 25, 2027.
How long does Mira Pharmaceuticals (MIRA) have to fix its Nasdaq bid price deficiency?
Mira has an initial 180 calendar days, until January 25, 2027, to restore compliance. Under certain conditions, it may be eligible to seek an additional 180‑day period to cure the deficiency.
Is Mira Pharmaceuticals (MIRA) still listed on the Nasdaq Capital Market?
Yes. The Nasdaq notice has no immediate effect on Mira’s listing status. Its common stock continues to trade on the Nasdaq Capital Market under the symbol MIRA while the company works within the compliance period.
What happens if Mira Pharmaceuticals (MIRA) cannot regain Nasdaq compliance?
If Mira does not regain compliance and is ineligible for or unable to use an extended cure period, Nasdaq may move to delist its common stock. Mira could then appeal a delisting determination to a Nasdaq Hearings Panel, but success is not assured.
What options might Mira Pharmaceuticals (MIRA) consider to cure the bid price deficiency?
Mira intends to monitor its share price and may consider available options to regain compliance. The notice specifies that an additional cure period could involve plans to address the deficiency, potentially including a reverse stock split if necessary.